Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$10.66|
|52 Week High||US$7.21|
|52 Week Low||US$16.37|
|1 Month Change||15.87%|
|3 Month Change||9.56%|
|1 Year Change||42.13%|
|3 Year Change||65.27%|
|5 Year Change||n/a|
|Change since IPO||11.62%|
Recent News & Updates
|ALPN||US Biotechs||US Market|
Return vs Industry: ALPN exceeded the US Biotechs industry which returned 28.4% over the past year.
Return vs Market: ALPN exceeded the US Market which returned 36.2% over the past year.
Stable Share Price: ALPN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ALPN's weekly volatility (8%) has been stable over the past year.
About the Company
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products.
Alpine Immune Sciences Fundamentals Summary
|ALPN fundamental statistics|
Is ALPN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALPN income statement (TTM)|
|Cost of Revenue||US$40.28m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.45|
|Net Profit Margin||-190.22%|
How did ALPN perform over the long term?See historical performance and comparison
Is Alpine Immune Sciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ALPN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ALPN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ALPN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ALPN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALPN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALPN is overvalued based on its PB Ratio (5.8x) compared to the US Biotechs industry average (3.2x).
How is Alpine Immune Sciences forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALPN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ALPN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ALPN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ALPN's revenue is expected to decline over the next 3 years (-12.7% per year).
High Growth Revenue: ALPN's revenue is forecast to decline over the next 3 years (-12.7% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ALPN's Return on Equity is forecast to be high in 3 years time
How has Alpine Immune Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALPN is currently unprofitable.
Growing Profit Margin: ALPN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALPN is unprofitable, and losses have increased over the past 5 years at a rate of 32% per year.
Accelerating Growth: Unable to compare ALPN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALPN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: ALPN has a negative Return on Equity (-77.92%), as it is currently unprofitable.
How is Alpine Immune Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: ALPN's short term assets ($139.7M) exceed its short term liabilities ($60.2M).
Long Term Liabilities: ALPN's short term assets ($139.7M) exceed its long term liabilities ($55.7M).
Debt to Equity History and Analysis
Debt Level: ALPN's debt to equity ratio (23.4%) is considered satisfactory.
Reducing Debt: ALPN's debt to equity ratio has increased from 1.1% to 23.4% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALPN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALPN has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 6% each year.
What is Alpine Immune Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALPN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALPN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALPN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALPN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALPN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mitch Gold (53 yo)
Dr. Mitchell H. Gold, also known as Mitch, M.D., has been Executive Chairman and Chief Executive Officer at Alpine Immune Sciences Inc. since January 2015 and June 2016 respectively. Dr. Gold served as the...
CEO Compensation Analysis
Compensation vs Market: Mitch's total compensation ($USD1.38M) is about average for companies of similar size in the US market ($USD1.09M).
Compensation vs Earnings: Mitch's compensation has been consistent with company performance over the past year.
Experienced Management: ALPN's management team is considered experienced (2.3 years average tenure).
Experienced Board: ALPN's board of directors are considered experienced (4.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Alpine Immune Sciences, Inc.'s employee growth, exchange listings and data sources
- Name: Alpine Immune Sciences, Inc.
- Ticker: ALPN
- Exchange: NasdaqGM
- Founded: 2007
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$254.933m
- Shares outstanding: 23.91m
- Website: https://www.alpineimmunesciences.com
Number of Employees
- Alpine Immune Sciences, Inc.
- 188 East Blaine Street
- Suite 200
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/23 23:07|
|End of Day Share Price||2021/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.